1. Written informed consent and HIPAA authorization for release of personal health
information prior to registration. NOTE: HIPAA authorization may be included in the
informed consent or obtained separately.
2. Age ≥ 18 years at the time of consent. No dosing or adverse event data are currently
available on the use of ipilimumab in combination with nivolumab in patients < 18
years of age.
3. ECOG Performance Status of 0-1 within 28 days prior to registration.
4. Patients must have clinically confirmed ocular melanoma diagnosed by a retinal
specialist or ocular oncologist. NOTE: Patients with cutaneous melanoma, acral
melanoma, mucosal melanoma, or conjunctival melanoma are ineligible.
5. Patients must have ocular melanoma that is considered high-risk for recurrence as
defined by one of the following criteria:
- Gene Expression Profile using 15-gene panel (Castle Bioscience) and be classified
as Class 2, or
- 3-year recurrent risk of more than 50% as defined by Impact Genetics, or
- Monosomy of chromosome 3 with apical tumor height > 8mm (53).
6. Archival tumor tissue is required for subjects that have had enucleation; subjects
that have had enucleation but do not have available archival tissue are not eligible
for participation. Archival tissue is required if available for subjects that have not
had enucleation; if not available these patients are still eligible.
7. Patients must have undergone an adequate treatment for the primary ocular melanoma
deemed appropriate by the treating physician.
8. All disease must be treated with no clinical, or radiologic evidence of residual
ocular melanoma. All participants must have disease-free status documented by a
complete physical examination and imaging studies within 4 weeks prior to
registration. Imaging studies must include CT or MRI scans of the chest, abdomen, and
pelvis. Brain MRI should be performed only as clinically indicated. NOTE: Participants
with equivocal nodes ≥ 10 mm and < 15 mm in a short axis may be eligible after if
confirmation with histology/cytology is available. If risk of biopsy is too high or
biopsy is not feasible, two sequential CT or MRI scans should be available and showing
no signs of progressive and measurable disease or PET/CT demonstrating no FDG uptake.
The second scan should occur at least 4 weeks after the initial scan. Lymph nodes ≥ 10
mm in a short axis are defined as pathological. Nodes that have a short axis <10 mm
are considered non-pathological.
9. Patients must be registered within 180 days of the last treatment performed to render
the patient free of disease.
10. Patient may have received prior radiation therapy to the primary site, including after
the surgical resection. No systemic radiation for metastatic ocular melanoma is
11. Subject re-enrollment: This study permits the re-enrollment of a participant who has
discontinued the study as a screen failure. If re-enrolled, the participant must be
12. Demonstrate adequate organ function as defined in the table below. All screening labs
to be obtained within 28 days prior to registration.
- Absolute Neutrophil Count (ANC) ≥ 1,500 cells/mm3
- Platelets ≥ 100,000 cells/mm3
- Hemoglobin (Hgb) ≥ 9 g/dL (NOTE: The use of transfusion or to achieve Hgb ≥ 10
g/dl is acceptable)
- Serum creatinine ≤ 1.5 x institutional upper limit normal (IULN) OR eGFR >
30mL/min for participant with creatinine levels > 1.5 x ULN
- Bilirubin ≤ 1.5 x IULN (except subjects with Gilbert Syndrome who can have total
bilirubin ≥ 3.0 mg/dL)
- Aspartate aminotransferase (AST) ≤ 3.0 x IULN
- Alanine aminotransferase (ALT) ≤ 3.0 x IULN
- Alkaline phosphatase ≤ 2.5 IULN
13. Neuropathy (sensory and motor) Grade ≤ 1 (CTCAE v4)
14. Females of childbearing potential must have a negative serum pregnancy test at
screening and within 24 hours prior to initiation of study treatment. NOTE: Females
are considered of child bearing potential unless they are surgically sterile (have
undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they
are naturally postmenopausal for at least 12 consecutive months.
15. Females of childbearing potential and non-vasectomized males must be willing to
abstain from heterosexual activity or to use 2 forms of effective methods of
contraception from the time of informed consent until 5 months after last dose of
study drug (females) and 7 months after last dose of study drug for (males). The two
contraception methods can be comprised of two barrier methods, or a barrier method
plus a hormonal method.
16. As determined by the enrolling physician or protocol designee, ability of the subject
to understand and comply with study procedures for the entire length of the study
1. Patients with evidence of distant metastases (stage IV ocular melanoma) are not
2. Patients with local or orbital recurrence are not eligible.
3. Patients with cutaneous, mucosal, acral or conjunctival melanoma are not eligible.
4. Subjects with active, known, or suspected autoimmune disease. Subjects with Type I
diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders
(such as vitiligo, psoriasis or alopecia) not requiring systemic treatment or
conditions not expected to recur in the absences of an external trigger are permitted
5. Subjects with a condition requiring systemic treatment with either corticosteroids (>
10 mg daily prednisone equivalents) or other immunosuppressive medications within 2
years of study drug administration. Inhaled or topical steroids and adrenal
replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of
active autoimmune disease.
6. Participants with previous malignancies are excluded unless a complete remission was
achieved at 12 months prior to study entry and no additional therapy is required or
anticipated to be required during the study period (exceptions include but are not
limited to, non-melanoma skin cancers; in situ bladder cancer, in situ gastric cancer,
or in situ colon cancer; in situ cervical cancer/dysplasia; or breast carcinoma in
7. History of Grade ≥ 3 allergy to human monoclonal antibodies.
8. Subjects who have had prior immunotherapy, including but not limited to interferon
alfa-2b, PEG-IFN, anti-PD-1, anti-PD-L1, anti-CTLA4 intra-tumoral or vaccine therapies
are not permitted to enroll.
9. Psychological, familial, sociological, or geographical conditions that potentially
hamper compliance with the study protocol and follow-up schedule; those conditions
should be discussed with the participant before registration in the trial.
10. Subjects who are receiving any other investigational agents.
11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (requiring systemic therapy), symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
would limit compliance with study requirements.
12. Patients known history of positive test for human immunodeficiency virus (HIV) or
known acquired immunodeficiency syndrome (AIDS). Note: Testing for HIV must be
performed at sites where mandated locally.
13. Subjects who are unable or unwilling to discontinue use of prohibited medications.
14. Subject is a prisoner